Larimar Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| LARIMAR THERAPEUTICS, INC. | |
| By: | /s/ Carole S. Ben-Maimon, M.D. |
| Name: Carole S. Ben-Maimon, M.D. | |
| Title: President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Carole S. Ben-Maimon, M.D. | President, Chief Executive Officer and Director (principal executive officer) | March 14, 2024 |
| Carole S. Ben-Maimon, M.D. | ||
| /s/ Michael Celano | Chief Financial Officer(principal financial and accounting officer) | March 14, 2024 |
| Michael Celano | ||
| /s/ Joseph Truitt | Chairman, Board of Directors | March 14, 2024 |
| Joseph Truitt | ||
| /s/ Thomas E. Hamilton | Director | March 14, 2024 |
| Thomas E. Hamilton | ||
| /s/ Jonathan Leff | Director | March 14, 2024 |
| Jonathan Leff | ||
| /s/ Jeffrey W. Sherman, M.D., FACP | Director | March 14, 2024 |
| Jeffrey W. Sherman, M.D., FACP | ||
| /s/ Frank E. Thomas | Director | March 14, 2024 |
| Frank E. Thomas | ||
INDEX
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-1 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Changes in Stockholders Equity for the years ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.